Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed diffuse large B-cell non-Hodgkin's lymphoma according to REAL classification~  * Diagnosed within the past 6 weeks~ * CD20+ disease~ * Ann Arbor stage II, III, or IV disease or stage I bulky disease~* International Prognostic Index (IPI) score of 0 or 1~  * Score 0 defined by all of the following:~    * Stage I or II disease~   * ECOG performance status of 0 or 1~   * Lactic dehydrogenase (LDH) no greater than upper limit of normal (ULN)~ * Score 1 defined by 1 of the following:~    * Stage I or II disease; ECOG performance status of 0 or 1; and LDH greater than ULN~   * Stage I or II disease; ECOG performance status 2 or 3; and LDH no greater than ULN~   * Stage III or IV disease; ECOG performance status 0 or 1; and LDH no greater than ULN~* Previously untreated disease~* Mediastinal B-cell lymphoma allowed~* No secondary lymphoma after prior chemotherapy or radiotherapy for other malignancies~* No transformed lymphoma~* No primary CNS lymphoma~* No primary gastrointestinal (MALT) lymphoma~* No post-transplant lymphoproliferative disorder~PATIENT CHARACTERISTICS:~Age~* 18 to 60~Performance status~* See Disease Characteristics~* ECOG 0-3~Life expectancy~* At least 3 months~Hematopoietic~* Not specified~Hepatic~* Bilirubin no greater than 2.0 mg/dL\*~* Transaminases no greater than 3 times normal\*~* No active chronic hepatitis B or C infection NOTE: \*Unless related to lymphoma~Renal~* Creatinine no greater than 2 times normal\* NOTE: \*Unless related to lymphoma~Cardiovascular~* No myocardial infarction within the past 6 months~* No uncompensated heart failure~* No dilatative cardiomyopathy~* No coronary heart disease with ST segment depression on ECG~* No severe uncompensated hypertension~Pulmonary~* No chronic lung disease with hypoxemia~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* HIV negative~* No known allergic reactions against foreign proteins~* No other prior malignancy except basal cell skin cancer or carcinoma in situ of the cervix~* No concurrent disease that would preclude study treatment~* No active infections requiring systemic antibiotics or antiviral medications~* No severe uncompensated diabetes mellitus~* No clinical signs of cerebral dysfunction~* No severe psychiatric disease~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior murine antibodies~Chemotherapy~* No other concurrent anticancer chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No concurrent response-adapted (slow response or unconfirmed complete response) radiotherapy~Surgery~* Not specified~Other~* No prior lymphoma-specific treatment~* More than 12 weeks since prior participation in another clinical trial~* No prior participation in this study~* No other concurrent study medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Arm A: CHOP-21 (Type: ACTIVE_COMPARATOR): Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle: day 22 Total number of cycles 6
- Arm B: CHOP-21 + Rituximab (Type: ACTIVE_COMPARATOR): Rituximab 375 mg/m² i.v. day 1\* Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6

Based on this trial design, predict the completion outcome and termination type (if applicable).